Pricing of drugs and donations: options for sustainable equity pricing

Authors: Pérez-Casas C.; Herranz E.; Ford N.

Source: Tropical Medicine & International Health, Volume 6, Number 11, November 2001 , pp. 960-964(5)

Publisher: Wiley-Blackwell

Abstract:

Effective medicines exist to treat or alleviate many diseases which predominate in the developing world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines. Increasingly, drug donations have been established by drug companies, but these are often limited in time, place or use. Measures exist which are more sustainable and will have a greater positive impact on people’s health. Principally, these are encouraging generic competition; adopting into national legislation and implementing TRIPS safeguards to gain access to cheaper sources of drugs; differential pricing; creating high volume or high demand through global and regional procurement; and supporting the production of quality generic drugs by developing countries through voluntary licenses if needed, and facilitating technology transfer.

Keywords: pricing; donation; generic drug; compulsory licensing; parallel import; leishmaniasis; trachoma; azithromycin; cryptococcal meningitis; fluconazole; antiretrovirals

Language: English

Document Type: Research article

Publication date: 2001-11-01

• In this: publication
• By this: publisher
• In this Subject: Internal Medicine
• By this author: Pérez-Casas C. ;  Herranz E. ;  Ford N.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers